Pages that link to "Q48398973"

The following pages link to Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. (Q48398973):

Displaying 48 items.

• The dopamine theory of addiction: 40 years of highs and lows (Q22251015) (← links)
• Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development (Q27014737) (← links)
• Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design (Q28828620) (← links)
• In vivo imaging of cerebral dopamine D3 receptors in alcoholism. (Q33620597) (← links)
• Dopamine D₃ receptor alterations in cocaine-dependent humans imaged with [¹¹C](+)PHNO. (Q33809050) (← links)
• Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans (Q33905597) (← links)
• The simplified reference tissue model with 18F-fallypride positron emission tomography: choice of reference region. (Q33921691) (← links)
• Measurement error analysis for the determination of dopamine D(2) receptor occupancy using the agonist radioligand [(11)C]MNPA. (Q34170757) (← links)
• Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO (Q34356950) (← links)
• Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner (Q34362666) (← links)
• The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro (Q34661099) (← links)
• Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors (Q34918396) (← links)
• Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders (Q35143623) (← links)
• A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [(11)C](+)PHNO (Q35952369) (← links)
• Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO. (Q36113455) (← links)
• Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO. (Q36610068) (← links)
• Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task (Q36636329) (← links)
• Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers (Q36730787) (← links)
• Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study. (Q36798993) (← links)
• Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO (Q37280384) (← links)
• Tracer kinetic modeling of [(11)C]AFM, a new PET imaging agent for the serotonin transporter (Q37365633) (← links)
• Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO (Q37409577) (← links)
• Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand (Q37449728) (← links)
• Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD (Q37536347) (← links)
• Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET. (Q37584225) (← links)
• Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO. (Q37662436) (← links)
• Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use (Q37705759) (← links)
• Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders (Q38056059) (← links)
• Dopamine D3 receptor antagonists: a patent review (2007 - 2012). (Q38071135) (← links)
• Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography (Q38244707) (← links)
• The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [(11) C]-raclopride and [(11) C]-(+)-PHNO PET. (Q38650497) (← links)
• Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. (Q39037300) (← links)
• Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. (Q39635324) (← links)
• The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study (Q40029733) (← links)
• Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding (Q41993350) (← links)
• Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. (Q43277003) (← links)
• Deep TMS of the insula using the H-coil modulates dopamine release: a crossover [11C] PHNO-PET pilot trial in healthy humans (Q47571269) (← links)
• Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia (Q47596297) (← links)
• A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [11 C]-(+)-PHNO. (Q47745261) (← links)
• Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans (Q48170494) (← links)
• First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study (Q48218651) (← links)
• Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: A positron emission tomography study with [11C]-(+)-PHNO. (Q49963882) (← links)
• Therapeutic doses of buspirone block D3 receptors in the living primate brain. (Q52304391) (← links)
• Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry (Q57138468) (← links)
• DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum (Q64777182) (← links)
• On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study (Q89747549) (← links)
• Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans (Q91117925) (← links)
• Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study (Q101403283) (← links)